Results 161 to 170 of about 1,724,249 (286)

Antibiotic Use for Cystitis and Risk of Treatment Failure in Pregnancy Following Gastric Bypass: A Cohort Study

open access: yesBasic &Clinical Pharmacology &Toxicology, Volume 139, Issue 5, November 2026.
ABSTRACT Cystitis is common during pregnancy and requires effective antibiotic treatment to prevent complications. Gastric bypass surgery alters gastrointestinal anatomy and may impair oral drug absorption, raising concerns about antibiotic effectiveness.
Mette Østergaard Thunbo   +5 more
wiley   +1 more source

GLP‐1 Receptor Agonists Post‐Bariatric Surgery (GRABS) Trial: Rationale, Design and Baseline Characteristics

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 9861-9870, November 2026.
ABSTRACT Aims No studies have investigated the synergistic effectiveness of Glucagon‐Like Peptide 1 Receptor Agonists (GLP1RAs) in patients with persistent obesity following bariatric surgery. The GLP‐1 Receptor Agonists Post‐Bariatric Surgery (GRABS) Trial aims to investigate the effectiveness of tirzepatide (TRZ) versus standard of care (SOC) after ...
J. M. Samuels   +12 more
wiley   +1 more source

The Lupus Damage Index Revision Program: Results From the Item Generation and Reduction Phases

open access: yesArthritis Care &Research, Volume 78, Issue 10, Page 1449-1466, October 2026.
Objective A data‐driven and expert/patient consensus‐based project to develop a revised Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) Damage Index (SDI) is under way supported by SLICC, ACR, and the Lupus Foundation of America. Our objective is to report the item generation and reduction phase results
Burak Kundakci   +25 more
wiley   +1 more source

Targeting GALNT7 Disrupts the TAZ O‐GalNAcylation Feedback Loop to Suppress Gallbladder Cancer Progression

open access: yesAdvanced Science, Volume 13, Issue 55, 5 October 2026.
Aberrant GALNT7‐mediated O‐GalNAcylation stabilizes TAZ to drive gallbladder cancer progression through a feed‐forward transcriptional loop. Structure‐based screening identifies Olaparib as a potent GALNT7 antagonist that disrupts this oncogenic axis, providing an immediate therapeutic strategy for this aggressive malignancy.
Peng Qiu   +11 more
wiley   +1 more source

CCNE1: A Cell Cycle Regulator That Influences Tumor Progression

open access: yesCancer Medicine, Volume 15, Issue 10, October 2026.
ABSTRACTCyclin E1 (CCNE1), a pivotal member of the cyclin family, governs the G1/S phase transition of the cell cycle by binding to and activating cyclin‐dependent kinase 2 (CDK2), thereby initiating DNA replication and driving S‐phase entry. In a broad spectrum of human malignancies—including breast, ovarian, gastric, and non‐small cell lung cancers ...
Liang Yan   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy